Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

F100 Selected publications

Epstein-Barr virus infectious particles initiate B cell transformation and modulate cytokine response.
Baccianti F, Masson C, Delecluse S, Li Z, Poirey R, Delecluse HJ.
mBio. 2023 Oct 31;14(5):e0178423. doi: 10.1128/mbio.01784-23.

Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven.
Cirac A#, Poirey R#, Dieckmeyer M, Witter K, Delecluse HJ, Behrends U, Mautner J.
Front Immunol. 2021 Dec 16;12:796379. doi: 10.3389/fimmu.2021.796379. (# contributed equally)
The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth.
Li Z, Baccianti F, Delecluse S, Tsai MH, Shumilov A, Cheng X, Ma S, Hoffmann I, Poirey R, Delecluse HJ.
Proc Natl Acad Sci U S A. 2021 Oct 26;118(43):e2115508118. doi: 10.1073/pnas.2115508118.
Identification and Cloning of a New Western Epstein-Barr Virus Strain That Efficiently Replicates in Primary B Cells.
Delecluse S, Poirey R, Zeier M, Schnitzler P, Behrends U, Tsai MH, Delecluse HJ.
J Virol. 2020 May 4;94(10):e01918-19. doi: 10.1128/JVI.01918-19
Spontaneous lymphoblastoid cell lines from patients with Epstein-Barr virus infection show highly variable proliferation characteristics that correlate with the expression levels of viral microRNAs.
Delecluse S, Yu J, Bernhardt K, Haar J, Poirey R, Tsai MH, Kiblawi R, Kopp-Schneider A, Schnitzler P, Zeier M, Dreger P, Wuchter P, Bulut OC, Behrends U, Delecluse HJ.
PLoS One. 2019 Sep 30;14(9):e0222847. doi: 10.1371/journal.pone.0222847.
Epstein-Barr virus nRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production.
Li Z, Tsai MH, Shumilov A, Baccianti F, Tsao SW, Poirey R, Delecluse HJ.
Nat Microbiol. 2019 Sep 9. doi: 10.1038/s41564-019-0546-y. [Epub ahead of print]
Progress in EBV Vaccines.
van Zyl DG, Mautner J, Delecluse HJ.
Front Oncol. 2019 Feb 25;9:104. doi: 10.3389/fonc.2019.00104. eCollection 2019. Review.
The Epstein-Barr virus induces the expression of the LPAM-1 integrin in B-Cells in vitro and in vivo.
Delecluse S, Tsai MH, Shumilov A, Bencun M, Arrow S, Beshirova A, Cottignies-Calamarte A, Lasitschka F, Bulut OC, Münz C, Zeier M, Behrends U, Delecluse HJ.

J Virol. 2018 Dec 12. Epub ahead of print

Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.
Schneidt V, Ilecka M, Dreger P, van Zyl DG, Fink S, Mautner J, Delecluse HJ.
Leukemia. 2019 Jan;33(1):88-98.

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice.
van Zyl DG, Tsai MH, Shumilov A, Schneidt V, Poirey R, Schlehe B, Fluhr H, Mautner J, Delecluse HJ.
PLoS Pathog. 2018 Dec 6;14(12):e1007464.

Antigen-armed antibodies against B-cell malignancies.
Ilecka M, van Zyl DG, Delecluse HJ.
Oncotarget. 2018 Nov 2;9(86):35601-35602.

Translational profiling of B cells infected with the Epstein-Barr virus reveals 5`leader ribosome recruitment through upstream open reading frames.
Bencun M, Klinke O, Hotz-Wagenblatt A, Klaus S, Tsai MH, Poirey R, Delecluse HJ.
Nucleic Acids Res. 2018 Apr 6;46(6):2802-2819.

Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression.
McHugh D, Caduff N, Barros MHM, Rämer PC, Raykova A, Murer A, Landtwing V, Quast I, Styles CT, Spohn M, Fowotade A, Delecluse HJ, Papoudou-Bai A, Lee YM, Kim JM, Middeldorp J, Schulz TF, Cesarman E, Zbinden A, Capaul R, White RE, Allday MJ, Niedobitek G, Blackbourn DJ, Grundhoff A, Münz C.
Cell Host Microbe. 2017 Jul 12;22(1):61-73.e7

Leflunomide/teriflumomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication.
Bilger A, Plowshay J, Ma S, Nawandar D, Barlow EA, Romero-Masters JC, Bristol JA, Li Z, Tsai MH, Delecluse HJ, Kenney SC.
Oncotarget. 2017 Jul 4;8(27):44266-44280

The Epstein-Barr virus and the centriole: new tricks from an old dog.
Delecluse HJ, Fink S, Tsai MH, Shumilov A.
Med Sci (Paris). 2017 Jun-Jul;33(6-7):567-569. doi: 10.1051/medsci/20173306003. Epub 2017 Jul 19. French. No abstract available.

Latent Membrane Protein 1 (LMP1) and LMP2A Collaborate To Promote Epstein-Barr Virsu-Induced B Cell Lymphomas in a Cord Blood-Humanized Mouse Model but are Not Essential.
Ma SD, Tsai MH, Romero-Masters JC, Ranheim EA, Huebner SM, Bristol JA, Delecluse HJ, Kenney SC.
J Virol. 2017 Mar 13;91(7). pii: e01928-16

Epstein-Barr virus particles induce centrosome amplification and chromosomal instability.
Shumilov A, Tsai MH, Schlosser YT, Kratz AS, Bernhardt K, Fink S, Mizani T, Lin X, Jauch A, Mautner J, Kopp-Schneider A, Feederle R, Hoffmann I, Delecluse HJ.
Nat Commun. 2017 Feb 10;8:14257

The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
Tsai MH, Lin X, Shumilov A, Bernhardt K, Feederle R, Poirey R, Kopp-Schneider A, Pereira B, Almeida R, Delecluse HJ.
Oncotarget. 2017 Feb 7;8(6):10238-10254

Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J, Malecka K, Wiedmer A, Delecluse HJ, Chiang AK, Altieri DC, Messick TE, Lieberman PM.
Oncotarget. 2017 Jan 31;8(5):7248-7264

The Epstein-Barr virus DNA load in the peripheral blood of transplant recipients does not accurately reflect the burden of infected cells.
Fink S, Tsai MH, Schnitzler P, Zeier M, Dreger P, Wuchter P, Bulut OC, Behrends U, Delecluse HJ.
Transpl Int. 2017 Jan;30(1):57-67

Epstein-Barr virus particles induce centrosome amplification and chromosomal instability.
Shumilov A, Tsai MH, Schlosser YT, Kratz AS, Bernhardt K, Fink S, Mizani T, Lin X, Jauch A, Mautner J, Kopp-Schneider A, Feederle R, Hoffmann I, Delecluse HJ.
Nat Commun. 2017 Feb 10;8:14257.

Fbxo28 promotes mitotic progression and regulates topoisomerase IIα-dependent DNA decatenation.
Kratz AS, Richter KT, Schlosser YT, Schmitt M, Shumilov A, Delecluse HJ, Hoffmann I.
Cell Cycle. 2016 Oct 18:1-13. [Epub ahead of print]

The Epstein-Barr virus DNA load in the peripheral blood of transplant recipients does not accurately reflect the burden of infected cells.
Fink S, Tsai MH, Schnitzler P, Zeier M, Dreger P, Wuchter P, Bulut OC, Behrends U, Delecluse HJ.
Transpl Int. 2016 Oct 7.

A viral microRNA cluster regulates the expression of PTEN, p27 and of a bcl-2 homolog
Bernhardt K, Haar J, Tsai MH, Poirey R, Feederle R, Delecluse HJ.
PLoS Pathog. 2016 Jan 22;12(1):e1005405

Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types.
Feederle R, Klinke O, Kutikhin A, Poirey R, Tsai MH, Delecluse HJ.
Curr Top Microbiol Immunol. 2015;390(Pt 1):119-48

The expression of a viral microRNA is regulated by clustering to allow optimal B cell transformation.
Haar J, Contrant M, Bernhardt K, Feederle R, Diederichs S, Pfeffer S, Delecluse HJ.
Nucleic Acids Res. 2015 Dec 3. pii: gkv1330. [Epub ahead of print]

The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells.
Lin X, Tsai MH, Shumilov A, Poirey R, Bannert H, Middeldorp JM, Feederle R, Delecluse HJ.
PLoS Pathog. 2015 Dec 22;11(12):e1005344

KIT Mutation and Loss of 14q May Be Sufficient for the Development of Clinically Symptomatic Very Low-Risk GIST.
Klinke OK, Mizani T, Baldwin G, Bancel B, Devouassoux-Shisheboran M, Scoazec JY, Bringuier PP, Feederle R, Jauch A, Hinderhofer K, Taniere P, Delecluse HJ.
PLoS One. 2015 Jun 23;10(6):e0130149

Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells.
Yu X, Ilecka M, Bartlett EJ, Schneidt V, Bhat R, Mautner J, Feederle R, Delecluse HJ.
Blood. 2015 Mar 5;125(10):1601-10

A Locus Encompassing the Epstein-Barr Virus bglf4 Kinase Regulates Expression of Genes Encoding Viral Structural Proteins.
El-Guindy A, Lopez-Giraldez F, Delecluse HJ, McKenzie J, Miller G.
PLoS Pathog. 2014 Aug 28;10(8)

Adoptive Transfer of EBV Specific CD8+ T Cell Clones Can Transiently Control EBV Infection in Humanized Mice.
Antsiferova O, Müller A, Rämer PC, Chijioke O, Chatterjee B, Raykova A, Planas R, Sospedra M, Shumilov A, Tsai MH, Delecluse HJ, Münz C.
PLoS Pathog. 2014 Aug 28;10(8)

Nuclear translocation and regulation of intranuclear distribution of cytoplasmic poly(a)-binding protein are distinct processes mediated by two epstein barr virus proteins.
Park R, El-Guindy A, Heston L, Lin SF, Yu KP, Nagy M, Borah S, Delecluse HJ, Steitz J, Miller G.
PLoS One. 2014 Apr 4;9(4):e92593.

Natural killer cells prevent infectious mononucleosis symptoms.
Chijoke O, Lipmann A, Feederle R, Barros MHM, Krieg C, Marcenaro E, Antsiferova O, Landtwing V, Bossart W, Moretta A, Hassan R, Boyman O, Niedobitek G, Delecluse HJ, Capaul R, Muenz C.
Cell Rep 2013 Dec 25;5(6):1489-98.

Genetics of Epstein-Barr virus microRNAs.
Klinke O, Feederle R, Delecluse HJ.
Semin Cancer Biol. 2014 Mar 3. pii: S1044-579X(14)00026-1.

Spontaneous lytic replication and epitheliotropism define an epstein-barr virus strain found in carcinomas.
Tsai MH, Raykova A, Klinke O, Bernhardt K, Gärtner K, Leung CS, Geletneky K, Sertel S, Münz C, Feederle R, Delecluse HJ.
Cell Rep. 2013 Oct 31;5(2):458-70

Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA.
Yu KP, Heston L, Park R, Ding Z, Wang'ondu R, Delecluse HJ, Miller G.
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8176-81. doi: 10.1073/pnas.1301577110. Epub 2013 Apr 26.

A cluster of virus-encoded microRNAs accelerates acute systemic Epstein-Barr virus infection but does not significantly enhance virus-induced oncogenesis in vivo.
Wahl A, Linnstaedt SD, Esoda C, Krisko JF, Martinez-Torres F, Delecluse HJ, Cullen BR, Garcia JV.
J Virol. 2013 May;87(10):5437-46. doi: 10.1128/JVI.00281-13. Epub 2013 Mar 6.

An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.
Pavlova S, Feederle R, Gärtner K, Fuchs W, Granzow H, Delecluse HJ.
J Virol. 2013 Feb;87(4):2011-22. doi: 10.1128/JVI.02533-12. Epub 2012 Dec 12.

Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.
Heath E, Begue-Pastor N, Chaganti S, Croom-Carter D, Shannon-Lowe C, Kube D, Feederle R, Delecluse HJ, Rickinson AB, Bell AI.
PLoS Pathog. 2012 May;8(5):e1002697. Epub 2012 May 10.

The viral and cellular microRNA targetome in lymphoblastoid cell lines.
Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, Nusbaum JD, Feederle R, Delecluse HJ, Luftig MA, Tuschl T, Ohler U, Cullen BR.
PLoS Pathog. 2012 Jan;8(1):e1002484. Epub 2012 Jan 26.

EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription.
Tsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse HJ, Lieberman PM.
PLoS Pathog. 2011 Nov;7(11):e1002376. Epub 2011 Nov 10.

The members of an Epstein-Barr virus microRNA cluster cooperate to transform B lymphocytes.
Feederle R, Haar J, Bernhardt K, Linnstaedt SD, Bannert H, Lips H, Cullen BR, Delecluse HJ.
J Virol. 2011 Oct;85(19):9801-10. Epub 2011 Jul 13.

A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus.
Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ.
PLoS Pathog. 2011 Feb;7(2):e1001294. Epub 2011 Feb 17.

The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways.
Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, Delecluse HJ, Hislop AD, Rowe M.
J Virol. 2011 Feb;85(4):1604-14. Epub 2010 Dec 1.

Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.
Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A.
J Virol. 2010 Apr;84(7):3612-23. Epub 2010 Jan 20.

Epstein-Barr virus genetics: talking about the BAC generation.
Feederle R, Bartlett EJ, Delecluse HJ.
Herpesviridae. 2010 Dec 7;1(1):6.

Busse C, Feederle R, Schnölzer M, Behrends U, Mautner J, Delecluse HJ.
Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
J Virol. 2010, 8:1139-47.

Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, Zavolan M, Polacek N, Delecluse HJ, Hüttenhofer A.
Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome.
PLoS Pathog. 2009, 5:e1000547.

Feederle R, Bannert H, Lips H, Müller-Lantzsch N, Delecluse HJ.
The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication.
J Virol. 2009, 83:4952-62.

Neuhierl B, Feederle R, Adhikary D, Hub B, Geletneky K, Mautner J, Delecluse HJ.
Primary B cell infection with a ΔBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T cell response.
J Virol. 2009, 83: 4616-23.

Delecluse HJ, Feederle R, Behrends U, Mautner J.
Contributions of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Semin Cancer Biol. 2008, 18: 409-415.

Granato M, Feederle R, Farina A, Gonnella R, Santarelli R, Hub B, Faggioni A, Delecluse HJ.
Deletion of Epstein-Barr virus BFLF2 leads to impaired viral DNA packaging and primary egress as well as to the production of defective viral particles.
J Virol. 2008, 82:4042-51.

Adhikary D, Behrends U, Feederle R, Delecluse HJ, Mautner J.
Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles.
J Virol. 2008, 82: 3903-11

Feederle R, Neuhierl B, Bannert H, Geletneky K, Shannon-Lowe C, Delecluse HJ.
Epstein-Barr virus B95.8 produced in 293 cells shows marked tropism for differentiated primary epithelial cells and reveals inter-individual variation susceptibility to viral infection.
Int. J. Cancer. 2007, 121: 588-94

Feederle R, Neuhierl B, Baldwin G, Bannert H, Hub B, Mautner J, Behrends U, Delecluse HJ.
Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes.
J. Virol. 2006, 80: 9435-43

Feederle R, Shannon-Lowe C, Baldwin G, Delecluse HJ.
Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus.
J Virol. 2005 79: 7641-7

Neuhierl B & Delecluse HJ.
Molecular Genetics of DNA Viruses in "DNA Viruses: Methods and Protocols, 2004".
Methods Mol Biol. 2004; 292: 353-70

Feederle R & Delecluse HJ.
Low level of lytic replication in a recombinant Epstein-Barr virus carrying an origin of replication devoid of BZLF1 binding sites.
J Virol. 2004; 78:12082-4

Bhende PM, Seaman WT, Delecluse HJ, Kenney SC.
The EBV lytic switch protein Z preferentially binds to and activates the methylated viral genome.
Nat Genet, 2004; 36, 1099-1104

Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F, Delecluse HJ.
Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma
Lancet, 2003, 361; 217-23

Neuhierl B, Feederle R, Hammerschmidt H & Delecluse HJ.
Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.
PNAS, 2002, 99; 15036–15041

HJ Delecluse, M. Kost, W. Hammerschmidt.
An experimental system for the production of infectious particles carrying viral mutants of Kaposi's sarcoma associated virus.
J. Virol. 2001, 75; 2921-2928

Janz, M. Oezel, C. Kurzeder, J. Mautner, D. Pich, M. Kost, W. Hammerschmidt & HJ Delecluse.
An infectious Epstein-Barr virus lacking the major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.
J Virol. 2000, 21; 10142-52

R. Feederle, M. Kost, M. Baumann, A.Janz, E. Drouet, W. Hammerschmidt, & HJ Delecluse.
The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.
EMBO J. 2000, 19; 3080-89

HJ Delecluse, D Pich, T Hilsendegen, C Baum & W Hammerschmidt.
A first-generation packaging cell line for Epstein-Barr virus-derived vectors.
PNAS 1999, 96; 5188-93

HJ Delecluse, T Hilsendegen, D Pich, R Zeidler & W Hammerschmidt.
Propagation and recovery of intact, infectious Epstein-Barr Virus from prokaryotic to human cells.
PNAS 1998, 95; 8245-50

to top
powered by webEdition CMS